Table 1.
Correlations between PRPF19 and clinicopathological features.
| Variables | Total cases (n = 125) (%) | PRPF19 expression | p Value | |
|---|---|---|---|---|
| Low expression (n = 68) (%) | High expression (n = 57) (%) | |||
| Gender | ||||
| Male | 68 (54.4) | 36 (28.8) | 32 (25.6) | 0.857 |
| Female | 57 (45.6) | 32 (25.6) | 25 (20.0) | |
| Age (years) | ||||
| <60 | 48 (38.4) | 26 (20.8) | 22 (17.6) | 0.556 |
| ≥60 | 77 (61.6) | 42 (33.6) | 35 (28.0) | |
| Size (cm) | ||||
| <5 | 58 (46.4) | 40 (32.0) | 18 (14.4) | 0.004* |
| ≥5 | 67 (53.6) | 28 (22.4) | 39 (31.2) | |
| TNM stage | ||||
| I-II | 58 (46.4) | 39 (31.2) | 19 (15.2) | 0.011* |
| III-IV | 67 (53.6) | 29 (23.2) | 38 (30.4) | |
| Depth of tumor invasion | ||||
| T1-T2 | 25 (20.0) | 19 (15.2) | 6 (4.80) | 0.024* |
| T3-T4 | 100 (80.0) | 49 (39.2) | 51 (40.8) | |
| Lymph node metastasis | ||||
| N0 | 58 (46.4) | 39 (31.2) | 19 (15.2) | 0.022* |
| N1 | 27 (21.6) | 13 (10.4) | 14 (11.2) | |
| N2 | 40 (32.0) | 16 (12.8) | 24 (19.2) | |
| Liver metastasis | ||||
| M0 | 87 (69.6) | 54 (43.2) | 33 (26.4) | 0.011* |
| M1 | 38 (30.4) | 14 (11.2) | 24 (19.2) | |
| CEA level (ng/ml) | ||||
| <5 | 63 (50.4) | 36 (28.8) | 27 (21.6) | 0.592 |
| ≥5 | 62 (49.6) | 32 (25.6) | 30 (24.0) | |
*p < 0.05 was considered statistically significant.